CODX Co-Diagnostics: תחזית צמיחת רווחים לשנה הבאה

Shrinking demand for PCR tests has forced Co-Diagnostics, Inc. (CODX) to develop portable rapid diagnostics for small clinics. Patents for Co-Dx Design home systems serve as a hedge against dumping in an oversaturated sector. Shifts in target earnings per share estimates confirm this trend, where 72.90 captures the magnitude of this parameter. Revenues are based on the supply of DNA equipment and molecular tests for global medical centers.

When selecting stocks, asset reliability is determined by the projected return on equity. This indicator measures the expected percentage growth in earnings per share for the following year, currently reaching a value of 72.90. For Co-Diagnostics, Inc. (CODX), this calculation confirms the commercialization of new PCR systems and the stability of the R&D pipeline; therefore, the valuation of future earnings per share dynamics serves as a signal of the business's fundamental resilience.